News

Profusa Invests Additional $1 Million in Digital Treasury Assets

  • BERKELEY, Calif, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, announces its second $1 million investment in digital treasury assets to hedge against macroeconomic uncertainties, in line with the Company's treasury management strategy.
    10/07/2025

Profusa Adds a Leading French Critical Limb Ischemia Surgeon to Customer Base

  • Pr. Yann Gouëffic and affiliates (FRANCE-PAD) cover ~8% of all CLTI cases in France BERKELEY, Calif, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry, announces additional growth in its customer base in Europe, with a collaboration with Yann Gouëffic, M.D., Ph.D., professor of vascular surgery in the Vascular Center at Groupe Hospitalier Paris Saint Joseph, Paris, France and a leading surgeon in the field of critical limb threatening ischemia (CLTI).
    10/01/2025
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

The price of Profusa, Inc. Common Stock (PFSA) is 0.3383 and it was updated on 2025-10-10 02:07:41.

Currently Profusa, Inc. Common Stock (PFSA) is in undervalued.

News
    
News

Profusa Adopts NVIDIA-Powered Technology to Build AI-Driven Insight Portal for Continuous Biomarker Monitoring

  • Company expects early 2026 rollout in EEA; physician portal combines Lumee™ oxygen monitoring with NVIDIA NeMo to deliver AI-driven clinical workflows
    Thu, Sep. 11, 2025

Profusa Adds Head of Vascular Surgery Department at AZ Sint Blasius Hospital, Belgium to Growing Customer Base

  • Internationally recognized vascular surgeon, Dr. Koen Deloose provides patient access to latest innovative treatments and personalized care
    Thu, Sep. 04, 2025

Profusa Welcomes Former Acting U.S. Veterans Affairs Secretary Peter O'Rourke as Lead Independent Director; Adds Seasoned Finance Executive Fred Knechtel as CFO

  • Board addition served in the Trump Administration, overseeing 1,300 facilities serving more than 9 million veterans; New CFO has led finance and operations at companies including Northrop Grumman, Stanley Black & Decker, and DuPont
    Tue, Aug. 19, 2025

Profusa, Inc. Provides Strategy Overview and Business Update for Investors

  • BERKELEY, Calif, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, provides a strategy overview and business update from Chairman and CEO, Ben Hwang, Ph.D. in the following Letter to Shareholders:
    Wed, Aug. 06, 2025

Profusa Secures Lumee™ Oxygen Platform Distributor in Spain

  • BERKELEY, Calif, July 31, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces it has signed a Letter of Intent (LOI) to enter into a distribution agreement in Spain for its Lumee Oxygen platform. The Spanish distributor, Dismeval, S.L., specializes in the distribution of medical and surgical equipment throughout Spain, including the Canary and Balearic Islands. The distribution partner has an experienced and well trained team with in-depth knowledge of the medical device sector and hands-on expertise in supporting hospital-based clinical and technical operations.
    Thu, Jul. 31, 2025
More Headlines
News

Profusa Announces $100 Million Equity Line of Credit to Initiate Bitcoin Treasury Strategy

  • BERKELEY, Calif, July 21, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, today announced that it is initiating a Bitcoin treasury strategy via the execution of a Securities Purchase Agreement (the “ELOC”) with Ascent Partners Fund LLC, (“Ascent”), pursuant to which Ascent will purchase up to $100,000,000 of the Company's Common Stock. 100% of the net proceeds will be used to purchase Bitcoin (which can be used for debt repayment) provided that the Company's cash balance on the date of the put exceeds $5,000,000.
  • 07/21/2025
Unlock
PFSA Ratings Summary
PFSA Quant Ranking